Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4820587 | 0.98 | RAB9A (0.45) | RAB9ABCDIN3DLTA4HKDM4EHPGD | |
| SCHEMBL4669084 | 0.77 | RAB9A (0.46) | RAB9ABCDIN3DLTA4HKDM4EHPGD | |
| SCHEMBL4670579 | 0.77 | BCDIN3D (0.55) | RAB9ABCDIN3DLTA4HKDM4EHPGD | |
| Hydrochloric Acid SCHEMBL4821983 | 0.76 | SYK (0.39) | — | |
| Hydrochloric Acid SCHEMBL4825575 | 0.76 | RAB9A (0.45) | RAB9ABCDIN3DLTA4HKDM4EHPGD | |
| Hydrochloric Acid SCHEMBL4826139 | 0.75 | BCDIN3D (0.54) | RAB9ABCDIN3DLTA4HKDM4EHPGD | |
| Hydrochloric Acid SCHEMBL3775074 | 0.75 | ABL1 (0.38) | — | |
| SCHEMBL4670847 | 0.73 | TNF (0.38) | KDM4EGAA | |
| SCHEMBL4670843 | 0.73 | SLC6A2 (0.37) | — | |
| SCHEMBL4670529 | 0.72 | CHRNB2 (0.37) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100448848-C | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-01-07 | — | — | CN | claimed |
| EP-1757586-B1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | SERVIER LAB (FR) | 2008-12-03 | — | — | EP | claimed |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | claimed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | claimed |
| EP-1757586-A1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | Les Laboratoires Servier (FR) | 2007-02-28 | — | — | EP | claimed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | claimed |
| CN-1903844-A | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-31 | — | — | CN | claimed |
| CN-100448848-C | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-01-07 | — | — | CN | disclosed |
| EP-1757586-B1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | SERVIER LAB (FR) | 2008-12-03 | — | — | EP | disclosed |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | disclosed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | disclosed |
| EP-1757586-A1 | POLYSBUSTITUIRTE 1,1-PYRIDINYLAMINOCYCLOPROPANAMIN DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMATUETISCHE ZUSAMMENSETZUNG | Les Laboratoires Servier (FR) | 2007-02-28 | — | — | EP | disclosed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | disclosed |
| CN-1903844-A | New polysubstituted 1, 1pyridylaminocyclopropanamine compounds,a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | CHRNA1, CHRM1, CHRNA9 | RAB9A 1701/4885BCDIN3D 2620/4885LTA4H 693/4885 |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | CHRM1, CHRM2, CHRM3 | RAB9A 1492/4885BCDIN3D 1458/4885LTA4H 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.